跳至主要内容
临床试验/CTRI/2023/05/052877
CTRI/2023/05/052877进行中(未招募)不适用

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single oral dose, crossover, bioequivalence study of Ibuprofen 400 mg tablets of Pinnacle Life Science Pvt. Ltd., In comparison with Brufen® 400 mg Tablets (Ibuprofen 400 mg) of Famar A.V.E Anthoussa Plant Anthoussa in healthy, adult, human subjects under fasting conditions.

Pinnacle Life Science Pvt. Ltd.1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2023年5月26日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
24
试验地点
1
主要终点
Cmax and AUC0-t

研究概览

简要总结

Study Title: An open label, balanced, randomized,two-treatment, two-period, two-sequence, single oral dose, crossover,bioequivalence study of Ibuprofen 400 mg tablets of Pinnacle Life Science Pvt.Ltd., In comparison with Brufen® 400 mgTablets (Ibuprofen 400 mg) of Famar A.V.E Anthoussa Plant Anthoussa inhealthy, adult, human subjects under fasting  conditions.

Study Objectives:

Primaryobjective:

To compare the rate and extent of absorption of Ibuprofen400 mg tablets of Pinnacle Life Science Pvt. Ltd., withthat of with Brufen® 400 mg Tablets (Ibuprofen400 mg) of Famar A.V.E Anthoussa Plant Anthoussa in healthy, adult, humansubjects under fasting conditions.

Secondary objective:

Tomonitor the safety and tolerability of the study subjects after administrationof Ibuprofen 400 mg tablets under fasting conditions.

Study Duration: 09 Days

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Open Label

入排标准

年龄范围
18.00 Year(s) 至 45.00 Year(s)(—)
性别
All

入选标准

  • Able to comprehend the nature and purpose of the study and willing to give written informed consent for participation in the study.
  • Willing to be available for the entire study period and to comply with protocol requirements.
  • Normal, healthy, adult, human subject of 18-45 years (both inclusive) of age.
  • Body mass index in the range of 18.5 – 30 kg/m2 (both inclusive).

排除标准

  • Any medical or surgical condition, which might significantly interfere with the functioning of the gastrointestinal tract or blood–forming organs.
  • History or presence of gastric or duodenal ulcer or GI bleeding or blood in stools anytime in the past.
  • History of severe infection or major surgery in the past 6 months.
  • History of Minor surgery or fracture within the past 3 months.

结局指标

主要结局

Cmax and AUC0-t

时间窗: Day 01 - Day 09

次要结局

  • AUC0-∞, Tmax , AUC_%Extrap_obs, λz and t1/2(Day 01 - Day 09)

研究者

发起方
Pinnacle Life Science Pvt. Ltd.
申办方类型
Pharmaceutical industry-Indian

研究点 (1)

Loading locations...

相似试验